Onkologie 2020: 14(Suppl.A): 9-12 | DOI: 10.36290/xon.2020.028

Pembrolizumab in treating an 82-year-old female patient with NSCLC

Juraj Kultan
Klinika plicních nemocí a tuberkulózy, FN Olomouc

Elderly patients account for a substantial proportion of newly diagnosed lung cancer cases. Advanced chronological age is not considered a contraindication to active treatment; however, specific issues of this population have to be taken into account. We report a case of a patient who, despite her older age, has benefited from further evaluation and treatment of metastatic lung cancer with immunotherapy.

Keywords: lung cancer, PD-L1, pembrolizumab, elderly patients.

Published: June 2, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kultan J. Pembrolizumab in treating an 82-year-old female patient with NSCLC. Onkologie. 2020;14(Suppl.A / Onkologické kazuistiky 1):9-12. doi: 10.36290/xon.2020.028.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Raju S, Joseph R, Sehgal S. Review of checkpoint immunotherapy for the management of non-small cell lung cancer. Immunotargets Ther. 20181; 7: 63-75. doi: 10.2147/ITT.S125070. eCollection 2018. Go to original source... Go to PubMed...
    2. Lu M, Su Y. Immunotherapy in non-small cell lung cancer: The past, the present, and the future. Thorac Cancer. 2019; 10(4): 585-586. Go to original source... Go to PubMed...
    3. Wirsdörfer F, de Leve S, Jendrossek V. Combining Radiotherapy and Immunotherapy in Lung Cancer: Can We Expect Limitations Due to Altered Normal Tissue Toxicity?. Int J Mol Sci. 2018; 20(1): 24. Published 2018 Dec 21. Go to original source...
    4. www.svod.cz/graph/
    5. https://seer.cancer.gov/statfacts/html/lungb.html
    6. Dziechciaz M, Filip R. Biological psychological ans social determinants of old age: Bio-psycho-social aspects of human aging. Ann Agric Environ Med. 2014; 21(4): 835-838. doi: https://doi.org/10.5604/12321966.1129943 Go to original source... Go to PubMed...
    7. https://www.who.int/healthinfo/survey/ageingdefnolder
    8. Singh S, Bajorek B. Defining "elderly" in clinical practice guidelines for pharmacotherapy. Pharmacy Practice 2014; 12(4): 489s. Go to original source...
    9. Kelly CM, Shahrokni A. Moving beyond Karnofsky and ECOG Performance Status Assessments with New Technologies. J Oncol. 2016; 2016: 6186543. doi: 10.1155/2016/6186543 Go to original source...
    10. Jomrich G, Hollenstein M, John M, et al. The modified glasgow prognostic score is an independent prognostic indicator in neoadjuvantly treated adenocarcinoma of the esophagogastric junction. Oncotarget. 2018; 9(6): 6968-6976. Published 2018 Jan 8. Go to original source... Go to PubMed...
    11. Fulop T, Larbi A, Dupuis G et al. Immunosenescence and Inflamm-Aging As Two Sides of the Same Coin: Friends or Foes? Front. Immunol.
    12. Prelaj A, Tay R, Ferrara R et al. Predictive biomarkers of response for immune checkpoint inhibitors in non-small-cell lung cancer. European Journal of Cancer 2019; (106): 144-159. Go to original source... Go to PubMed...
    13. Nosaki K, Saka H, Hosomi Y, et al. Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies. Lung Cancer 2019; (135): 188-195. Go to original source... Go to PubMed...
    14. Marur S, Singh H, Mishra-Kalyani P, et al. FDA analyses of survival in older adults with metastatic non-small cell lung cancer in controlled trials of PD-1/PD-L1 blocking antibodies, Semin. Oncol. 2018; (14): 220-225. Go to original source... Go to PubMed...
    15. Muchnik E, Loh KP, Strawderman M, et al. Immune checkpoint inhibitors in real-world treatment of older adults with nonsmall cell lung cancer, J. Am. Geriatr. Soc. 2019; (35): 905-909. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.